Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sirolimus impairs wound healing.

Michael Schäffer1, Robert Schier, Markus Napirei

  • 1Department of Surgery, Chirurgische Universitätsklinik, Knappschaftskrankenhaus Bochum-Langendreer, In der Schornau 23-25, 44892 Bochum-Langendreer, Germany. michael.schaeffer@kk-bochum.de

Langenbeck'S Archives of Surgery
|March 27, 2007
PubMed
Summary

Sirolimus, an immunosuppressive drug, impairs wound healing by reducing collagen and vascular endothelial growth factor (VEGF) and nitric oxide expression in wounds.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent Mechanism.

ACS medicinal chemistry letters·2026
Same author

[Special considerations in geriatric anesthesiology : Aspects of perioperative management in older adults].

Zeitschrift fur Gerontologie und Geriatrie·2026
Same author

Association of Serum Uric Acid-Lowering Therapy and Resistance Index After Renal Transplantation.

Transplantation proceedings·2025
Same author

Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results.

The oncologist·2025
Same author

[Pancreas Transplantation].

Zentralblatt fur Chirurgie·2025
Same author

[Special considerations in geriatric anesthesiology : Aspects of perioperative management in older adults].

Die Anaesthesiologie·2025

Area of Science:

  • Immunology
  • Wound Healing Research
  • Pharmacology

Background:

  • Sirolimus is an immunosuppressive drug commonly used in organ transplantation.
  • Clinical observations suggest sirolimus may negatively impact wound healing.
  • The precise mechanisms by which sirolimus affects wound repair are not well understood.

Purpose of the Study:

  • To investigate the effects of sirolimus on wound healing in a preclinical model.
  • To analyze the expression of key mediators involved in angiogenesis and collagen synthesis, specifically vascular endothelial growth factor (VEGF) and nitric oxide, in response to sirolimus treatment.

Main Methods:

  • Rats received dorsal skin incisions and subcutaneous polyvinyl alcohol sponges.
  • Sirolimus was administered at doses of 0.5, 2.0, or 5.0 mg/kg/day.

Related Experiment Videos

  • Wound breaking strength, collagen deposition, and expression of VEGF and nitric oxide were assessed 10 days post-wounding.

    • Main Results:

    • Sirolimus significantly decreased splenic lymphocyte proliferation.
    • Wound fluid sirolimus concentrations were higher than blood levels.
    • Higher doses of sirolimus (2.0 and 5.0 mg/kg/day) reduced wound breaking strength and collagen deposition.
    • A parallel decrease in VEGF and nitric oxide expression was observed in the wounds.

    Conclusions:

    • Sirolimus demonstrably impairs wound healing in an experimental setting.
    • The impairment of wound healing by sirolimus is associated with reduced expression of VEGF and nitric oxide.
    • These findings provide mechanistic insights into the clinical observation of delayed wound healing in patients treated with sirolimus.